Novel radiotherapy may save increasingly many rectal cancer patients from surgery and a stoma
Tampere University Hospital (Tays) has begun offering a new form of radiotherapy to treat rectal cancer in which a high dose of radiation is targeted at the tumor surface. The aim is to destroy the tumor so that more patients may avoid major surgery and a potentially permanent stoma. Finland is at the forefront of implementing this novel treatment.
Tampere University Hospital in Finland has commenced offering a groundbreaking form of radiotherapy for rectal cancer patients, potentially enabling many to bypass major surgery and a permanent stoma. This innovative treatment, termed high-dose-rate brachytherapy or HDR brachytherapy, involves directing a strong dose of radiation precisely at the tumor's surface.
Unlike traditional surgery, which can lead to long-term complications, this method minimizes radiation exposure to healthy tissues. Professor Toni Seppälä from Tampere University and Tays Hospital explains that the primary objective is to cure cancer while preserving the patient's quality of life. The eligibility for this treatment is determined by a team of medical professionals including colorectal surgeons, oncologists, radiation oncologists, and radiologists.
While not suitable for all rectal cancer patients, it could be particularly beneficial for older or frail individuals who may face significant risks from major surgery. The introduction of this treatment aligns with the NORPPA research program, aiming to develop new organ-preserving strategies for rectal cancer. A future study will evaluate the treatment's effectiveness and safety, potentially expanding its application to more patients who may avoid major surgery altogether.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
